Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs KLA Corp. (KLAC) Price & Performance

Price performance (Past 24H)

Key statistics

GSK plc vs KLA Corp. — how do they compare? GSK plc trades at $50.44 (market cap $102.60B), while KLA Corp. trades at $209.03 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 2.6× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

GSKKLAC
Market Cap
$102.60B$261.92B
Sector
HealthTechnology
52-Week High
$61.18$301.71
52-Week Low
$38.22$84.39
Enterprise Value
$123.04B$263.17B
Dividend Yield
3.57%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

KLA Corp.

KLA Corporation (KLAC) trades at $209.16, up 8.52% over 24 hours, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a 35.57% net income margin and 87.5% ROE, supported by a recent dividend hike and stock split. Analyst consensus is bullish with a $246.93 price target, though elevated valuation ratios like a P/E of 54.77 warrant caution.

Outlook remains positive driven by AI-driven semiconductor equipment demand, but risks include high valuation sensitivity and cyclical industry exposure. The stock offers growth potential with disciplined risk management advised given overbought technical conditions and macroeconomic uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC